MACROGENICS®

MGD010: B-cell Inhibitory DART[®] Molecule Targeting CD79B & CD32B

Ph 1 First-in-Human, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, PK / PD & Immunogenicity of MGD010 in Healthy Subjects *[Abstract OP0201]*

Naimish Pandya, MD

10 June 2016





DISCLOSURES


• Employee of MacroGenics



European League Against Rheumatism

Introduction


- B cells play an important role in immune tolerance and autoimmunity
 - CD32B (FcyRIIb): a checkpoint molecule on B cells
 - CD79B: signal transducing component of B-cell receptor
- MGD010, a bi-specific Dual-Affinity Re-Targeting (DART[®]) molecule, inhibits B-cell activation
 - Co-ligation of CD32B with CD79B leverages a natural physiologic B-cell inhibitory loop, delivering a negative signal that limits B-cell activation
- MGD010 provides a novel therapeutic approach to autoimmune disorders
 - Non-depleting intervention (vs rituximab)
 - Rapid onset of activity (vs belimumab)





MGD010-mediated Inhibition of B-cell Function

Inhibition of B-cell Proliferation in vitro and Immunoglobulin Secretion in vivo



- Co-ligation of both targets is essential for functional activity of MGD010
 - Monospecific engagement of CD32B does not result in B-cell inhibition
 - Preclinical models confirm inhibitory properties of MGD010 with a decrease in B-cell proliferation and suppression of immunoglobulin secretion

Study Objectives

Primary Objective

– Assess safety and tolerability of single dose of MGD010 in healthy adult subjects

Secondary Objectives

- Evaluate single MGD010 dose pharmacokinetics
- Assess pharmacodynamics effects of MGD010 on humoral immune responses
- Evaluate potential anti-drug antibodies

Exploratory Objectives

- Evaluate MGD010 binding to CD32B and CD79B on peripheral B cells
- Evaluate activation status of peripheral B cells and B-cell subsets
- Assess immune phenotype, including modulation of B-cell subsets
- Assess response of peripheral B cells to ex-vivo BCR stimulation



Eligibility

- Key Inclusion criteria
 - Age: 18 50 years
 - BMI: 18 30 kg/m²

• Key Exclusion criteria

- Women of child bearing potential or who are pregnant and/or breastfeeding
- Medical history and concurrent diseases
 - Any significant acute or chronic medical illness (use of any prescription drugs within 4 wks of dosing or OTC drugs within 1 wk of dosing)
 - Major surgery within 4 wks of dosing
 - Smoking > 10 cigarettes per day
 - Infectious disease (TB, Hep B, Hep C, HIV)
 - Known history of autoimmune or vascular disorders
 - Physical and lab findings:
 - QTc > 450 msec, HR < 45 bpm or > 120 bpm, SBP > 140 mmHg, DBP > 90 mmHg
 - AST/ALT > 1.25 > ULN, Tbili > 1.25 x ULN, abnormal PT/PTT
 - Positive urine drug screen



Study Design

- Enrolled healthy volunteers in six escalation cohorts
 - Healthy volunteers represent homogeneous population to ascertain safety and pharmacodynamics effects of MGD010
- Eight subjects to enroll at each dose cohort
 - Six subjects were treated with MGD010 and two were treated with Placebo
- Staggered dosing at each dose cohort to assess safety & tolerability
 - Randomized 6 subjects in double-blind manner after treating two sentinel subjects with MGD010



Dose Cohort	MGD010 Dose (mg/kg)
1	0.01
2	0.1
3	0.3
4	1.0
5	3.0
6	10.0



Study Enrollment

Baseline Demographics							
Ν	49 ^a						
Age (yrs)	33.4 ± 7.4						
Gender (M:F)	48:1						
Race:							
White	12						
Black	35						
Other	2						
Mean Weight (kg)	78.0 ± 12.1						
Mean Height (cm)	177.5 ± 7.8						

^aForty-nine subjects were treated in Dose Escalation: 0.01, 0.1, 0.3, 1, 3 or 10 mg/kg MGD010

Adverse Events

Adverse Event*	All Events		Related		Advoras Eventt	All Events		Related	
	All	≥ Gr 3	All	≥ Gr 3	Adverse Event*	All	≥ Gr 3	All	≥ Gr 3
Conjunctival Haemorrhage	1	-	-	-	Periorbital contusion	1	-	-	-
Ocular Hyperemia	1	-	-	-	Muscle twitching	1	-	-	-
Pupils Unequal	1	-	-	-	Headache	3		3	-
Nausea	1	-	1	-	Somnolence	1	-	1	-
Chills	1	-	-	-	Terminal insomnia	1	-	-	-
Vessel puncture site bruise	1	-	-	-	Nasal congestions	1	-	-	-
Folliculitis	1	-	1	-	Rhinorrhea	1	-	1	-
Upper respiratory tract infection	2	-	2	-	Dry skin	1	-	-	-
Viral upper respiratory tract infection	2	-	-	-	Night sweats	1	-	1	-
Contusion	1	-	-	-	Pruritus	1	-	-	-
Ligament sprain	1	-	-	-	Rash	1		1	
Limb injury	1	-	-	-	Hypertension	1	1	-	-
Muscle strain	1	-	-	-					


*MedDRA Preferred Term


AEs assessed by 2007 FDA Guidance of Toxicity Grading Scale for healthy adult & adolescent volunteers enrolled in preventive vaccine clinical trials




Pharmacokinetics and Circulating B-cell Occupancy

- MGD010 serum concentrations increase linearly with dose
 - Half-life: ~8 days at \geq 1mg/kg
- Maximum B-cell occupancy at doses ≥1 mg/kg
 - Sustained receptor occupancy beyond one week at doses ≥ 1 mg/kg
- No B-cell depletion or cytokine release (data not shown) at any dose levels






Treatment with MGD010 Inhibited B-Cell Activation




- PBMCs from enrolled subjects collected longitudinally after MGD010 treatment
 - Ca²⁺ flux (hallmark of B-cell activation) induced *ex vivo* by B-cell receptor ligation using anti-IgM
 - Data normalized to maximum Ca²⁺ permeability (maximum induction) via ionomycin
- Dose dependent B-cell inhibition demonstrated with increasing doses of MGD010

 Inhibition sustained for several weeks at highest dose levels

MGD010 Modulated Cell Surface BCR and Serum Ig Levels



MGD010 Impacts Naïve & Mature B-cells




A single MGD010 dose in healthy volunteers:

- Modulated naïve and mature B-cell signal transduction via signaling blockade and/or down-regulation of surface Ig
- Decreased serum IgM levels, suggesting an impact on plasmablasts
 - Lack of CD79B expression on plasma cells is consistent with no effect on other serum Ig



MGD010 Reduced B-cell CD40 Expression



- MGD010 has potential impact on B-cell : T-cell interactions
 - Decreased cell surface expression of CD40, a B cell co-stimulatory molecule
 - No effect on other cell surface markers observed
 - HLA-DR (as shown), CD80/86, CD69, CD25

Summary

MGD010 is well tolerated as single dose up to 10 mg/kg in healthy subjects

- 1. No B-cell activation or cytokine release
- 2. No depletion of peripheral B cells
- 3. BCR saturated at ≥ 1mg/kg dose levels with sustained receptor occupancy with increasing doses

MGD010 down-modulated B-cell function at multiple levels

- 1. Reduction in BCR-induced Ca²⁺ mobilization
- 2. Decrease surface lg expression
- 3. Decrease serum IgM levels

Data supports continued development of MGD010 in patients with autoimmune disorders



Acknowledgements

- In sincere appreciation to all volunteer subjects enrolled in this study for their contributions
- Contributors to MGD010 Program
 - Parexel International Corporation
 - Ronald Goldwater, MD
 - MacroGenics
 - Wei Chen, MD
 - Joanna Lohr, PhD
 - Xiao-Tao Yao
 - Robert Burns
 - Hiaquan Li
 - Hua Li
 - John Muth
 - Neely Gal-Edd
 - Syd Johnson, PhD
 - Paul Moore, PhD
 - Jon Wigginton, MD
 - Ezio Bonvini, MD
 - Scott Koenig, MD, PhD

